As activist Starboard teams up with former Pfizer executives, the pharma giant’s lack of focus is in the spotlight.

Pfizer in recent months has implemented aggressive cost-cutting measures to help it weather the steep decline in sales of its ...

A trade group representing large compounding pharmacies sued the FDA over its removal of a widely prescribed Lilly diabetes ...

Discover the major biotech partnerships, collaborations and mergers and acquisitions that made headlines in September 2024.

Weight loss treatments are rapidly becoming a focal point for pharma R&D, driven by the commercial success of Eli Lilly and ...

Pfizer (PFE) stock may present opportunities for patient investors. Read how this biotech giant may deliver long-term ...

Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...

There aren’t a lot of easy changes the drugmaker can make to right itself quickly. Boosting sales fast enough to lift shares will be hard, and high debts rule out a game-changing acquisition. Get the ...

Among the large drugmakers, Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer are worth retaining in one’s portfolio.

Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.